The endocannabinoid system and neuropathic pain

Full item page Simple item page

• dc.contributor.author Maldonado, Rafael, 1961-ca
• dc.contributor.author Baños i Díez, Josep Eladica
• dc.contributor.author Cabañero Ferri, Davidca
• dc.date.accessioned 2018-06-04T07:46:13Z
• dc.date.available 2018-06-04T07:46:13Z
• dc.date.issued 2016
• dc.description.abstract The research of new therapeutic strategies for neuropathic pain represents a major current priority. Important drawbacks to advance in the development of these therapies are the limited translational value of the animal models now available and the elucidation of the complex neuronal and immune pathophysiological mechanisms underlying neuropathic pain. One of the neurotransmitter systems participating in neuropathic pain control that has recently raised a particular interest is the endocannabinoid system. This system is highly expressed in neurons and immune cells, and it plays a crucial role in the development of neuropathic pain. Preclinical studies have provided important findings, revealing the potential interest of the endocannabinoid system for the treatment of neuropathic pain. These studies have reported the analgesic effects of cannabinoid agonists in multiple neuropathic pain models, and they have identified specific targets within this system to develop more effective and safe analgesic compounds. However, further studies using more relevant neuropathic pain animal models are required to confirm these interesting results. Several clinical studies suggest that cannabinoids significantly reduced neuropathic pain, although most of these trials fail the required standards of quality. The different pain patient populations included in the systematic reviews also make it difficult to get adequate conclusions. Therefore, additional clinical trials that consider an adequate number of patients, the use active treatments as controls, and longer duration of administration are required to have an adequate profile of the effectiveness and safety of cannabinoids in neuropathic pain.
• dc.description.sponsorship This work was supported by the "Ministerio de Economía y Competitividad-MINECO" (SAF2011-29846 and #SAF2014-59648-P), the "Instituto de Salud Carlos III" (RETICS-RTA, #RD12/0028/0023), the "Generalitat de Catalunya-AGAUR" (#2014-SGR-1547) and the European Commission (NeuroPain, #HEALTH-F2-2013-602891) to R.M. The authors have no conflict of interest to declare with regards to this review.
• dc.format.mimetype application/pdf
• dc.identifier.citation Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016 Feb; 157 Suppl 1: S23-32. DOI: 10.1097/j.pain.0000000000000428
• dc.identifier.doi http://dx.doi.org/10.1097/j.pain.0000000000000428
• dc.identifier.issn 0304-3959
• dc.identifier.uri http://hdl.handle.net/10230/34808
• dc.language.iso eng
• dc.publisher Lippincott Williams & Wilkinsca
• dc.relation.ispartof Pain. 2016 Feb; 157 Suppl 1: S23-32
• dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/602891
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/SAF2011-29846
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2014-59648-P
• dc.rights © Lippincott Williams & Wilkins. This is a non-final version of an article published in final form in Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016 Feb; 157 Suppl 1: S23-32. http://dx.doi.org/10.1097/j.pain.0000000000000428
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Cannabidiol
• dc.subject.keyword Cannabis-based medicine
• dc.subject.keyword Neuropathic pain
• dc.title The endocannabinoid system and neuropathic painca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion